Earnings Call Summary | Exact Sciences(EXAS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Exact Sciences(EXAS.US) Q1 2024 Earnings Conference
The following is a summary of the Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript:
以下是Exact Sciences Corporation（EXAS）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Exact Sciences reported a 6% revenue increase in Q1 to $638 million.
The GAAP gross margin was 70%, slightly lower YoY due to additional costs of automation.
The company suffered a net loss of $110 million while the adjusted EBITDA was $39 million.
Tourism ended the quarter with cash and securities worth $652 million.
Exact Sciences報告稱，第一季度收入增長了6％，達到6.38億美元。
GAAP毛利率爲70％，由於自動化成本的增加，同比略低。
該公司淨虧損1.1億美元，調整後的息稅折舊攤銷前利潤爲3,900萬美元。
旅遊業在本季度末獲得了價值6.52億美元的現金和證券。
Business Progress:
業務進展：
They tested over 1 million people for cancer and rare diseases and witnessed an increased adoption of its Cologuard product.
International ordering providers for Oncotype DX grew over 20% YoY; their hereditary cancer test risk guard was brought to the oncology channel.
Results of the pivotal BLUE-C study were published, supporting the approval of Cologuard Plus by FDA.
To cater to their increasing AI and Microsoft Cloud business, investments are being made in cloud infrastructure.
The company expects annual revenue between $2.81 billion and $2.85 billion.
Despite a dip in orders per practice, Exact Sciences is keen on Cologuard's potential and plans on enhancing its sales and marketing team.
With a growing market of eligible patients for Cologuard, Exact Sciences anticipates significant growth.
The corporation plans to deliver blood test results by fall, which they expect will perform on par or better than other competitors in the field.
他們對超過100萬人進行了癌症和罕見疾病檢測，並見證了其Cologuard產品的採用率越來越高。
Oncotype DX的國際訂購提供商同比增長了20％以上；他們的遺傳性癌症測試風險警衛被帶到了腫瘤學頻道。
這項關鍵的BLUE-C研究的結果已經公佈，支持美國食品藥品管理局批准Cologuard Plus。
爲了滿足他們不斷增長的人工智能和微軟雲業務，正在對雲基礎設施進行投資。
該公司預計年收入在28.1億美元至28.5億美元之間。
儘管每家診所的訂單有所下降，但Exact Sciences仍熱衷於Cologuard的潛力，並計劃加強其銷售和營銷團隊。
隨着符合Cologuard條件的患者市場的不斷增長，Exact Sciences預計將大幅增長。
該公司計劃在秋季之前公佈血液檢查結果，他們預計該領域的表現將與該領域的其他競爭對手持平或更好。
More details: Exact Sciences IR
更多詳情： 精確科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。